Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Multinational study demonstrates positive effects of laquinimod in patients with RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced results from a 36-week active extension study evaluating two doses of laquinimod, an investigational, once-daily oral immunomodulator, for the treatment of relapsing remitting multiple sclerosis.

21 Sep 2010

Global dementia costs hit $604 billion: World Alzheimer Report 2010

The total estimated worldwide costs of dementia are $604 billion in 2010, according to the newly released World Alzheimer Report 2010, The Global Economic Impact of Dementia from Alzheimer's Disease International (ADI), a London based, nonprofit, international federation of 73 national Alzheimer organizations, including the Alzheimer's Association (U.S.).

21 Sep 2010

Crestor suppressed human cancer cells transplanted to mice

A drug commonly prescribed for people with high cholesterol may also be effective in treating prostate cancer, according to new research by Dr. Xiao-Yan Wen at St. Michael's Hospital.

20 Sep 2010

Harbor BioSciences granted US patent for Triolex metabolic disease and anti-inflammation drug candidate

Harbor BioSciences, Inc. today announced that the company has received patent No. 7,776,845 from the United States Patent and Trademark Office which covers its lead metabolic disease and anti-inflammation drug candidate Triolex (HE3286). The patent claims cover compounds including Triolex and formulations that contain the drug or the other claimed compounds.

20 Sep 2010

Chronix Biomedical completes Series E financing

Chronix Biomedical today announced that it has completed a Series E financing that raised $1.8 million from existing and new investors. Chronix is developing disease-specific biomarkers based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells. Chronix's serum DNA biomarkers are applicable to a wide range of cancers and other chronic diseases.

20 Sep 2010

CBC members, patient advocacy organizations offer support for PRIME Act

In a presentation today at the Congressional Black Caucus Foundation's Annual Legislative Conference Health Braintrust meeting, Faina Shtern, M.D., president and CEO of AdMeTech Foundation, unveiled overwhelming support from Congressional Black Caucus members and patient advocacy organizations for the Prostate Research, Imaging, and Men's Education Act of 2010.

18 Sep 2010

PCF applauds new prostate cancer legislation

As hundreds of prostate cancer researchers, advocates and supporters Advance on Washington this week and push for more progress in fighting the disease, the Prostate Cancer Foundation applauds the prostate cancer legislation introduced on Tuesday by Senator Jon Tester of Montana.

17 Sep 2010

HHS awards grant to develop patient-centered outcomes research

U.S. Department of Health and Human Services (HHS) Assistant Secretary for Health, Howard K. Koh, MD, MPH, today announced the award of more than $14 million to develop, implement, and test strategies to increase the adoption and dissemination of interventions based on patient-centered outcomes research among racial and ethnic minority populations.

16 Sep 2010

Johns Hopkins offers sources who can answer queries on prostrate cancer

September 19-25 is National Prostate Cancer Awareness Week. If you are planning a story on prostate cancer, a disease that's diagnosed in more than 200,000 American men each year, please consider calling on experts from the Johns Hopkins Brady Urological Institute.

16 Sep 2010

CINJ experts available for discussion during National Prostate Cancer Awareness Month

The Cancer Institute of New Jersey (CINJ) is making experts available to discuss the risks, treatments and prevention options surrounding prostate cancer during September, which is National Prostate Cancer Awareness Month. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

15 Sep 2010

Phase II clinical trial shows GTx-758 reduces serum free testosterone

GTx, Inc. today announced that in a Phase II, open label, pharmacokinetic-pharmacodynamic clinical trial, GTx-758, an oral selective estrogen receptor alpha agonist being developed to treat advanced prostate cancer, suppressed serum total testosterone to castrate levels, increased serum SHBG (sex hormone binding globulin), and markedly reduced serum free testosterone in healthy male volunteers.

15 Sep 2010

Organizations issue five-point plan to accelerate research, discovery of effective prostate cancer treatments

With $3 billion spent on the over-treatment of prostate cancer each year, new discoveries are prompting the prostate cancer community to Advance on Washington the week of September 13 - 18. This initiative calls for renewed commitments to finding answers that will enable physicians to cure more and over-treat less. The nation's leading prostate cancer organizations today issued a five point plan, targeted to policymakers, to accelerate research and discovery of effective prostate cancer treatments.

15 Sep 2010

TNS NIPO study underlines need for wide-scale, reliable prostate cancer screening

A recent TNS NIPO survey, on behalf of the Dutch Association of Urology (NVU) and the European Association of Urology (EAU), showed that almost four out of 10 Dutch men of 50 years and older suffer, or have suffered, from urinary complaints. The same number of men also said in the same survey they are worried that they may have prostate cancer.

15 Sep 2010

Harbor BioSciences releases Apoptone clinical trial data for castration resistant prostate cancer

Harbor BioSciences, Inc. a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released new positive data from its ongoing Phase I/IIa clinical trial with Apoptone(HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.

15 Sep 2010

Researchers develop new blood test to predict prostate cancer risk

A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan-Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings, published today online in the British Medical Journal, could have important implications for determining which men should be screened after the age of 60 and which may not benefit substantially from continued prostate cancer screening.

15 Sep 2010

Progenics Pharmaceuticals presents findings of humanized monoclonal antibodies against C. difficile bacterium

Progenics Pharmaceuticals, Inc. today presented preclinical findings for its humanized monoclonal antibodies against the disease-causing toxins produced by the bacterium Clostridium difficile.

14 Sep 2010

Men with low PSA level does not benefit further treatment: Study

Men aged 55 to 74 years who have low baseline blood levels of prostate specific antigen (PSA) are not likely to benefit from further screening and treatment. That is the conclusion of a new study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. The aim of the study is to help physicians and patients weigh the pros and cons of prostate cancer screening and early detection.

13 Sep 2010

Measuring PSA levels effective in detecting prostate cancer: Study

A new multinational study suggests that regular blood testing to measure levels of prostate specific antigen (PSA) is more effective at detecting prostate cancer in men with a genetic predisposition to the disease.

13 Sep 2010

PCRI to host educational event on prostate cancer therapy

Dean Ornish MD, recognized for establishing the impact of diet on prostate cancer (and heart disease), along with over a dozen internationally recognized prostate cancer experts will meet with over 800 prostate cancer survivors and their significant others at the Los Angeles Marriott near LAX on September 11th and 12th to discuss the latest thinking on prostate cancer treatment.

13 Sep 2010

Pennsylvania Bio issues new report on Pennsylvania's bioscience companies' efforts for cancer research

Pennsylvania Bio today issued a new report on cancer that details the research happening through Pennsylvania companies to develop new products to diagnose and treat cancer.

12 Sep 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Multinational study demonstrates positive effects of laquinimod in patients with RRMS

Global dementia costs hit $604 billion: World Alzheimer Report 2010

Crestor suppressed human cancer cells transplanted to mice

Harbor BioSciences granted US patent for Triolex metabolic disease and anti-inflammation drug candidate

Chronix Biomedical completes Series E financing

CBC members, patient advocacy organizations offer support for PRIME Act

PCF applauds new prostate cancer legislation

HHS awards grant to develop patient-centered outcomes research

Johns Hopkins offers sources who can answer queries on prostrate cancer

CINJ experts available for discussion during National Prostate Cancer Awareness Month

Phase II clinical trial shows GTx-758 reduces serum free testosterone

Organizations issue five-point plan to accelerate research, discovery of effective prostate cancer treatments

TNS NIPO study underlines need for wide-scale, reliable prostate cancer screening

Harbor BioSciences releases Apoptone clinical trial data for castration resistant prostate cancer

Researchers develop new blood test to predict prostate cancer risk

Progenics Pharmaceuticals presents findings of humanized monoclonal antibodies against C. difficile bacterium

Men with low PSA level does not benefit further treatment: Study

Measuring PSA levels effective in detecting prostate cancer: Study

PCRI to host educational event on prostate cancer therapy

Pennsylvania Bio issues new report on Pennsylvania's bioscience companies' efforts for cancer research

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in